Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Declares Quarterly Dividend of $0.94

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced a quarterly dividend on Monday, November 2nd. Investors of record on Friday, November 20th will be paid a dividend of $0.94 per share by the biopharmaceutical company on Thursday, December 3rd. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Friday, November 20th.

Regeneron Pharmaceuticals has a payout ratio of 9.6% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Regeneron Pharmaceuticals to earn $53.12 per share next year, which means the company should continue to be able to cover its $3.76 annual dividend with an expected future payout ratio of 7.1%.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded up $33.37 during mid-day trading on Monday, reaching $961.26. 1,656,990 shares of the company were exchanged, compared to its average volume of 826,516. The firm has a market cap of $98.97 billion, a PE ratio of 21.22, a PEG ratio of 1.57 and a beta of 0.10. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.06 and a quick ratio of 3.66. The company has a fifty day simple moving average of $793.30 and a 200-day simple moving average of $738.05. Regeneron Pharmaceuticals has a 12 month low of $591.52 and a 12 month high of $974.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $16.51 by $3.56. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. Regeneron Pharmaceuticals’s quarterly revenue was up 36.3% on a year-over-year basis. During the same period in the prior year, the firm posted $11.83 EPS. As a group, equities research analysts expect that Regeneron Pharmaceuticals will post 49.10 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on REGN. Canaccord Genuity Group increased their price objective on shares of Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the stock a “buy” rating in a research note on Wednesday, October 28th. Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,100.00 and gave the company a “buy” rating in a research report on Monday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, September 21st. The Goldman Sachs Group increased their price target on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Evercore boosted their price objective on shares of Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $898.97.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.